· Published by Health Canada · Official notice
This is duplicated text of a letter from Janssen Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 21, 2014
Subject: Risk of rare serious skin conditions in patients treated with STELARA® (ustekinumab)
Janssen Inc., in consultation with Health Canada, would like to inform you about important new safety information regarding the risk of rare serious skin conditions (exfoliative dermatitis and erythrodermic psoriasis) which have been reported in patients treated with STELARA®.
STELARA® is a medication used to treat moderate to severe plaque psoriasis and/ or psoriatic arthritis.
Janssen Inc. is working with Health Canada to update the safety information for STELARA® and has sent a letter to health care professionals to inform them of this new important safety information. A copy of that letter is available on the Health Canada Web site. This information is also available on the Janssen Inc. Web site.
If you have any questions regarding your treatment with STELARA®, please contact your doctor.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious skin reactions or other serious or unexpected side effects in patients receiving STELARA® should be reported to Janssen Inc. or Health Canada.
Drug Safety Department
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Or call toll-free 1-866-825-7122
Or email to dsscan@joica.jnj.com
Or fax to 1-866-787-5865
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738